Drug intelligence / Profile preview

S-CW3554

Development stage: Preclinical
Lead developer: Case Western Reserve University
Modality: Small Molecules

Overview

S-CW3554 is an irreversible, selective inhibitor of protein disulfide isomerase (PDI). It contains a 2-chloropropionamide functionality, allowing it to covalently and selectively label and inhibit PDI enzymatic activity. This compound has demonstrated unique cytotoxicity in cell lines derived from multiple myeloma, suggesting research interest in its potential anti-cancer effects and in targeting cellular protein-folding homeostasis. It is classified as a synthetic small molecule probe for research or early-stage pharmaceutical development, but is not widely documented in public therapeutic or commercial databases[1][4][7].

Other names: EVT-1535526EVT1535526EVT 1535526

Targets

P4HB (Protein disulfide-isomerase)

Beyond the preview

Go deeper on S-CW3554.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S-CW3554.

Explore the full profile